Francesco Orlandi
Commissariat à l'Énergie Atomique et aux Énergies Alternatives(FR)Université Paris-Saclay(FR)CEA Paris-Saclay(FR)Institut de Recherche sur les Lois Fondamentales de l'Univers(FR)
Publications by Year
Research Areas
Particle physics theoretical and experimental studies, High-Energy Particle Collisions Research, Quantum Chromodynamics and Particle Interactions, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC(2018)3,693 cited
- → Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial(2019)924 cited
- → Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)(2021)778 cited
- → Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study(2020)740 cited
- → IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC(2021)495 cited
- → Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial